Integrated analysis of microRNA-target interactions with clinical outcomes for cancers

BMC Medical Genomics

Volumn 7, Issue SUPPL.1, 2014, Pages

  Joung, Je Gun ^a,c   Kim, Dokyoon ^a,b   Lee, Su Yeon ^a   Kang, Hwa Jung ^c   Kim, Ju Han ^a  

^a Seoul National University College of Medicine   (South Korea)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Samsung Medical Center   (South Korea)

Author keywords

Cancer Genes; Gene Expression Profile; miRNA Expression; miRNA mRNA interaction; Survival Analysis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; MICRORNA; MICRORNA 124; MICRORNA 148B; MICRORNA 196A; MICRORNA 374B; MICRORNA 98; MITOCHONDRIAL TUMOR SUPPRESSOR 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; INTEGRATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN RNA BINDING; RNA ANALYSIS; SURVIVAL RATE; BIOLOGY; FEMALE; GENETICS; OVARIAN NEOPLASMS; PROCEDURES; PROGNOSIS; SURVIVAL;

COMPUTATIONAL BIOLOGY; FEMALE; GLIOBLASTOMA; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TRANSCRIPTOME;

EID: 84900446710     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-7-S1-S10     Document Type: Article

References (41)

1. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, et al. Proc Natl Acad Sci USA 2003 100 12 6958 6963 10.1073/pnas.1131754100 12777628 (Pubitemid 36706375)
2. A gene-expression signature as a predictor of survival in breast cancer. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. The New England journal of medicine 2002 347 25 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
3. Gene expression profiling predicts clinical outcome of breast cancer. vant Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Nature 2002 415 6871 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
4. Predicting the clinical status of human breast cancer by using gene expression profiles. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Marks JR, Nevins JR, Proc Natl Acad Sci USA 2001 98 20 11462 11467 10.1073/pnas.201162998 11562467 (Pubitemid 32928751)
5. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J, Wainscoat JS, et al. Journal of cellular and molecular medicine 2009 13 7 1248 1260 10.1111/j.1582-4934.2008.00628.x 19413891
6. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al. British journal of haematology 2008 141 5 672 675 10.1111/j.1365-2141.2008.07077.x 18318758 (Pubitemid 351667616)
7. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, et al. International journal of cancer Journal international du cancer 2007 121 5 1156 1161 10.1002/ijc.22800 17487835 (Pubitemid 47101656)
8. MicroRNA gene expression deregulation in human breast cancer. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al. Cancer research 2005 65 16 7065 7070 10.1158/0008-5472.CAN-05-1783 16103053 (Pubitemid 41161233)
9. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al. The New England journal of medicine 2005 353 17 1793 1801 10.1056/NEJMoa050995 16251535 (Pubitemid 41549891)
10. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al. Cancer research 2004 64 11 3753 3756 10.1158/0008-5472.CAN-04-0637 15172979 (Pubitemid 38697282)
11. genomics, biogenesis, mechanism, and function. Bartel DP, MicroRNAs, Cell 2004 116 2 281 297 10.1016/S0092-8674(04)00045-5 14744438 (Pubitemid 38167318)
12. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Volinia S, Croce CM, Proc Natl Acad Sci USA 2013 110 18 7413 7417 10.1073/pnas.1304977110 23589849
13. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J, Cancer research 2011 71 17 5635 5645 10.1158/0008-5472.CAN-11-0489 21737487
14. Graph based fusion of miRNA and mRNA expression data improves clinical outcome prediction in prostate cancer. Gade S, Porzelius C, Falth M, Brase JC, Wuttig D, Kuner R, Binder H, Sultmann H, Beissbarth T, BMC Bioinformatics 2011 12 488 10.1186/1471-2105-12-488 22188670
15. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, et al. PLoS One 2012 7 3 34546 10.1371/journal.pone. 0034546 22479643
16. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Ronneberg JA, Johnsen H, Navon R, Rodland E, et al. PLoS One 2011 6 2 16915 10.1371/journal.pone.0016915 21364938
17. Semi-supervised methods to predict patient survival from gene expression data. Bair E, Tibshirani R, PLoS biology 2004 2 4 108 10.1371/journal.pbio. 0020108 15094809 (Pubitemid 39234509)
18. Integrated genomic analyses of ovarian carcinoma. TCGA Network, Nature 2011 474 7353 609 615 10.1038/nature10166 21720365
19. Synergistic effect of different levels of genomic data for cancer clinical outcome prediction. Kim D, Shin H, Song YS, Kim JH, J Biomed Inform 2012 45 6 1191 1198 10.1016/j.jbi.2012.07.008 22910106
20. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M, Gerangelos S, Koziris N, Dalamagas T, Hatzigeorgiou AG, Nucleic acids research 2012 40 Database 222 229 22135297
21. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y, Xu HM, Oncology reports 2012 27 2 447 454 21971665
22. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. Delfino KR, Rodriguez-Zas SL, PLoS One 2013 8 3 58608 10.1371/journal.pone.0058608 23554906
23. Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Chang H, Zhou X, Wang ZN, Song YX, Zhao F, Gao P, Chiang Y, Xu HM, Molecular medicine reports 2012 5 5 1277 1280 22344713
24. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J, Carcinogenesis 2010 31 5 766 776 10.1093/carcin/bgp250 19843643
25. MicroRNAs and the hallmarks of cancer. Dalmay T, Edwards DR, Oncogene 2006 25 46 6170 6175 10.1038/sj.onc.1209911 17028596 (Pubitemid 44527847)
26. Patterns of known and novel small RNAs in human cervical cancer. Lui WO, Pourmand N, Patterson BK, Fire A, Cancer research 2007 67 13 6031 6043 10.1158/0008-5472.CAN-06-0561 17616659 (Pubitemid 47037482)
27. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y, Cancer research 2009 69 14 5970 5977 10.1158/0008-5472.CAN-09-0236 19567675
28. LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer. Abdollahi A, Pisarcik D, Roberts D, Weinstein J, Cairns P, Hamilton TC, The Journal of biological chemistry 2003 278 8 6041 6049 10.1074/jbc.M210361200 12473647 (Pubitemid 36800855)
29. Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer. Xiao J, Chen JX, Zhu YP, Zhou LY, Shu QA, Chen LW, Oncology letters 2012 4 1 113 118 22807972
30. FEZ1/LZTS1 protein expression in ovarian cancer. Califano D, Pignata S, Pisano C, Greggi S, Laurelli G, Losito NS, Ottaiano A, Gallipoli A, Pasquinelli R, De Simone V, et al. Journal of cellular physiology 2010 222 2 382 386 10.1002/jcp.21962 19885841
31. Tumor promoting properties of the ETS protein MEF in ovarian cancer. Yao JJ, Liu Y, Lacorazza HD, Soslow RA, Scandura JM, Nimer SD, Hedvat CV, Oncogene 2007 26 27 4032 4037 10.1038/sj.onc.1210170 17213815 (Pubitemid 46884297)
32. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, Spendlove I, Durrant LG, Clinical cancer research: an official journal of the American Association for Cancer Research 2007 13 14 4139 4145 10.1158/1078-0432.CCR-06-2833 17634541 (Pubitemid 47105976)
33. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, et al. Cancer Res 2009 69 19 7569 7576 10.1158/0008-5472.CAN-09-0529 19773441
34. MiR-106a is an independent prognostic marker in patients with glioblastoma. Zhao S, Yang G, Mu Y, Han D, Shi C, Chen X, Deng Y, Zhang D, Wang L, Liu Y, et al. Neuro Oncol 2013 15 6 707 717 10.1093/neuonc/not001 23416698
35. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Zhang C, Kang C, You Y, Pu P, Yang W, Zhao P, Wang G, Zhang A, Jia Z, Han L, et al. Int J Oncol 2009 34 6 1653 1660 19424584
36. Role of microRNA-26b in glioma development and its mediated regulation on EphA2. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, Cao S, Lin X, PLoS One 2011 6 1 16264 10.1371/journal.pone.0016264 21264258
37. Increased expression of microRNA-17 predicts poor prognosis in human glioma. Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B, J Biomed Biotechnol 2012 2012 970761 23226946
38. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, et al. Clin Cancer Res 2009 15 21 6541 6550 10.1158/1078-0432.CCR-09-0695 19861460
39. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. Lubin M, Lubin A, PLoS One 2009 4 5 5735 10.1371/journal.pone.0005735 19478948
40. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. Nobusawa S, Stawski R, Kim YH, Nakazato Y, Ohgaki H, Neuropathology 2011 31 6 583 588 10.1111/j.1440-1789.2011.01204.x 21382095
41. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Tribius S, Pidel A, Casper D, Int J Radiat Oncol Biol Phys 2001 50 2 511 523 10.1016/S0360-3016(01)01489-4 11380241 (Pubitemid 32472281)